Organization | The Geneva Foundation

The Geneva Foundation Report issue

Foundation Phase 2 Phase 4

Founded: Tacoma WA United States (1993)

Organization Overview

First Clinical Trial

2005

NCT00207311

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Geneva Foundation | The Geneva Foundation

Active Ingredients

Drugs in Phase 4 Trials (6)

blood plasma (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

lidocaine (xylocaine) (1 trial)

orlistat (xenical) (1 trial)

ribavirin (virazole) (1 trial)

triamcinolone (kenalog) (1 trial)

Drugs in Phase 2 Trials (1)

mogroside (1 trial)

Drugs in Other Trials (4)

autologous mesenchymal stem cells (1 trial)

pioglitazone (actos) (1 trial)

platelet-rich plasma (1 trial)

propofol (diprivan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Fatty Liver (Phase 4)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis C (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 7
# of Trial APIs: 11